Philadelphia University + Thomas Jefferson University
Sidney Kimmel Medical College
Department of Dermatology & Cutaneous Biology

Alexeev, Vitali

< Back

Profile

vxa101

Vitali Y. Alexeev, PhD

Contact Dr. Alexeev

Bluemle Life Sciences Building, Room 430
233 South Tenth Street
Philadelphia, PA 19107

(215) 503-5434

Medical School

PhD Cell Biology, Institute of Cytology, Russian Academy of Science - 1996

Research and Clinical Interests

My current, vaccine-related research is focused on the analysis of the chemokines’ activity during immune response induction and on the development of chemokine-mediated strategies of immune response stimulation. My laboratory recently assessed the applicability of the secondary lymphoid chemokine, CCL21 for stimulation of melanoma-specific immune responses (Novak L, Igoucheva O, Cho S, Alexeev V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Molecular cancer therapeutics 2007;6 (6):1755-64). My laboratory is currently working on the development of practically applicable approaches for the treatment of cutaneous melanomas using chemokines in conjunction with (i) melanoma DNA vaccines and (ii) suicidal gene therapy.

In addition, I am collaborating with Dr. T. Sato (Department of Medical Oncology) on the research project related to the development on novel approaches of tumor-specific immune response induction using IL-10 antagonism.

The membership in the JVC will allow me to closely interact with researchers and clinicians, who are involved in the research, testing and application of anti-cancer vaccines, which potentially may lead to the establishment of new collaboration project. I believe, these interactions will also allow me to extend my knowledge in cancer vaccines and understanding of clinical needs.

Publications

Most Recent Peer-Reviewed Publications

  1. Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration
  2. CXCL12 as a Predictor of Vitiligo Activity and Disease Progression
  3. Prime-boost immunization eliminates metastatic colorectal cancer by producing high-Avidity effector CD8+T cells
  4. Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression
  5. High concordance between clinical diagnosis of epidermolysis bullosa and immunofluorescence with a small, well-matched antibody panel
  6. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment
  7. Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa
  8. Reaction Chemistry Generated by Nanosecond Pulsed Dielectric Barrier Discharge Treatment is Responsible for the Tumor Eradication in the B16 Melanoma Mouse Model
  9. Fibulin-4 E57K knock-in mice recapitulate cutaneous, vascular and skeletal defects of recessive cutis laxa 1B with both elastic fiber and collagen fibril abnormalities
  10. The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice
  11. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells
  12. Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound
  13. Human adipose-derived stem cell transplantation as a potential therapy for collagen VI-related congenital muscular dystrophy
  14. Chemokine-enhanced DNA vaccination in cancer immunotherapy
  15. Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine
  16. Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues
  17. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy
  18. Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder
  19. Targeted manipulation of mammalian genomes using designed zinc finger nucleases
  20. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: Immunoadhesins for human IL-10 with therapeutic potential